⌕
Boston Scientific · BSX · NYSE
Tenet 60 · Solid
Compare
$43.03−1.51%At closeTenet 60 · Solid
$43.03−0.66 (−1.51%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
$42.91−0.12 (−0.28%)
After hours: Nov 17, 2026, 7:58 PM ET

Boston Scientific (BSX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~14.0%/yr (FY21→FY25), net margin 14.4%, and free cash flow (~$3.7B) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($B)▲19.9%
20.1
FY21→FY25CAGR +14.0%/yr
Net income ($B)▲56.3%
2.9
one-off year: see footnoteCAGR +29.2%/yr
Free cash flow ($B)▲38.3%
3.7
FY21→FY25CAGR +29.1%/yr
Diluted EPS▲55.2%
1.94
FY21→FY25CAGR +29.5%/yr
What the receipts whisper · what a headline number hides
Share count
+4.2%

1.4bn → 1.5bn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.

Capex
$876.0M

steady at 4.4% of revenue (+10.9% YoY).

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($B)20.1Revenue−6.2COGS13.9Gross profit−2.1R&D−6.9SG&A3.6Op income−0.7Tax & other2.9Net income

14¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
705335180%sector median net margin ~3%FY21FY25

Over this window: gross 68.8% → 69.0%. Net margin 14.4% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
21,068.020,074.016,747.014,240.012,682.011,888.0▲19.9%+14.0%
Cost of revenue
6,502.06,221.05,257.04,345.03,956.03,711.0▲18.3%+13.8%
Gross profit
14,568.013,854.011,490.09,896.08,727.08,177.0▲20.6%+14.1%
Research & development
2,159.02,052.01,615.01,414.01,323.01,204.0▲27.1%+14.3%
Selling, general & admin
7,100.06,887.05,984.05,190.04,520.04,359.0▲15.1%+12.1%
Total operating expenses
10,637.010,241.08,887.07,553.07,079.06,978.0▲15.2%+10.1%
Operating incomefeeds ROC rank
3,932.03,613.02,603.02,343.01,649.01,199.0▲38.8%+31.8%
Other income, net
−277.0−228.0−321.0−358.0−508.0−123.0——
Pretax income
3,655.03,385.02,282.01,985.01,141.01,076.0▲48.3%+33.2%
Income tax
163.0493.0436.0393.0443.036.0▲13.1%+92.4%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
3,502.02,898.01,854.01,593.0698.01,041.0▲56.3%+29.2%
Per share
Diluted EPSbuyback-sensitive
2.361.941.251.070.450.69▲55.2%+29.5%
Diluted shares (bn)
1.451.491.491.461.441.43▲0.6%+1.0%
Margins
Gross margin56th pct in Healthcare
69.1%69.0%68.6%69.5%68.8%68.8%▲0.4pp+0.2pp
Operating margin
18.7%18.0%15.5%16.5%13.0%10.1%▲2.5pp+7.9pp
Net margin79th pct in Healthcare
16.6%14.4%11.1%11.2%5.5%8.8%▲3.4pp+5.7pp
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 3% vs a 19% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was 39% vs a 19% norm for this window, likely a one-time item; see the filing.
FY07 – FY20 · 14 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 14 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Boston Scientific's revenue last fiscal year?

Boston Scientific reported revenue of $20.1B in fiscal 2025, up 19.9% from fiscal 2024.

What was Boston Scientific's net income?

Boston Scientific reported net income of $2.9B in fiscal 2025, a net margin of 14.4%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.